1. Scientific conclusions and grounds for the amendment of the marketing authorisation of Neupro presented by the EMEA;European Medicines Agency,2009
2. Rotigotine: The first new chemical entity for transdermal drug delivery;McAfee;Eur J Pharm Biopharm,2014
3. Request to initiate Neupro down-titration;Bos,2008
4. Polymorphic form of rotigotine;Wolff;Patent WO,2009
5. Novel polymorphic form of rotigotine and process for production;Wolff,2009